Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPS vs SODIUM POLYSTYRENE SULFONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
Sodium polystyrene sulfonate is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the large intestine, thereby reducing serum potassium levels.
Treatment of hyperkalemia
Treatment of hyperkalemia
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
Adults: 15 g orally once daily to four times daily, as a single dose or suspension in water or syrup (3-4 m L per gram of resin). May also be administered rectally as a retention enema: 30-50 g every 6-8 hours, retained for at least 30-60 minutes.
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
The terminal elimination half-life of the absorbed fraction is not well-defined due to minimal systemic absorption; hence, half-life is not clinically relevant. The resin itself is not eliminated from the body via metabolism or excretion but is passed in feces.
SPS is not absorbed systemically and is excreted unchanged in the feces.
Sodium polystyrene sulfonate is not absorbed systemically; it acts locally in the gastrointestinal tract.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Primarily fecal (via gut) as the resin is not absorbed. Only a small fraction (approximately 0.5-1% of the administered dose) is absorbed, and the absorbed portion is eliminated renally as the sulfonate moiety. Renal elimination contributes minimally to total clearance (<1%).
Not applicable; SPS is not absorbed and does not bind to plasma proteins.
Negligible (<1%). The resin is not absorbed; therefore, protein binding of the intact resin is not applicable. The absorbed sulfonate moiety has negligible protein binding.
Not applicable; SPS remains within the gastrointestinal lumen and does not distribute into body tissues. Reported Vd is negligible.
Not applicable (Vd essentially 0 for the resin as it remains in the GI tract). For the absorbed fraction, Vd is minimal (<0.1 L/kg) due to rapid renal excretion.
Oral: 0% (not absorbed); rectal: 0% (not absorbed). SPS acts locally without systemic availability.
Oral: Essentially 0% absorbed (non-absorbable resin). Rectal: Similarly, systemic absorption is negligible (<0.5%).
No specific dose adjustment is recommended based on GFR. Use with caution in patients with renal impairment due to risk of electrolyte disturbances (e.g., hypernatremia, hypokalemia).
No specific dose adjustment is recommended based on GFR; however, use with caution in patients with renal impairment due to risk of electrolyte abnormalities and colonic necrosis. Alternative potassium-lowering agents are preferred in severe renal disease.
No dose adjustment required for hepatic impairment. Monitor serum electrolytes and fluid balance in patients with hepatic disease.
No specific Child-Pugh-based dose modifications are established. Use with caution in patients with hepatic impairment due to potential for fluid and electrolyte disturbances.
Children (2-12 years): 0.5-2 g/kg/day divided every 4-6 hours; maximum 30 g/day. Administer orally or rectally as per adult guidance.
Children: 1 g/kg orally per dose, given 1-4 times daily, or rectally as a retention enema: 1 g/kg per dose every 6-8 hours. Adjust based on serum potassium levels and body weight.
Use lowest effective dose; monitor electrolyte levels and renal function more frequently due to age-related decline in renal function and increased risk of electrolyte imbalance.
Elderly patients may be more susceptible to electrolyte imbalances and dehydration. Use the lowest effective dose and monitor serum potassium and sodium closely. Consider alternative therapy if risk of bowel ischemia or constipation is high.
No FDA black box warning.
No FDA black box warning.
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (e.g., hypokalemia, hypocalcemia, hypernatremia),Use with caution in patients with gastrointestinal disorders or postoperative patients
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (hypokalemia, hypocalcemia, hypomagnesemia),Sodium overload in patients with heart failure or hypertension,Use with caution in patients with severe constipation or impaction,Potential for aspiration if given orally to patients with impaired gag reflex
Hypokalemia,Obstructive bowel disease,Neonates with reduced gut motility (postoperative or drug-induced),Concurrent use with sorbitol
Hypersensitivity to sodium polystyrene sulfonate or any component,Obstructive bowel disease,Neonates with reduced gut motility (especially when given with sorbitol),Severe hypokalemia
Avoid high-potassium foods such as bananas, oranges, tomatoes, potatoes, and spinach to prevent excessive potassium intake. SPS may bind to some foods, but no specific food restrictions beyond potassium-rich foods are required. Do not mix SPS with fruit juices; use only water or simple syrup.
Avoid foods high in potassium (e.g., bananas, oranges, potatoes, spinach, avocados) and high-sodium foods to optimize potassium removal and prevent sodium overload. Do not mix SPS with juices containing potassium (e.g., orange juice). Maintain adequate fluid intake unless fluid-restricted. Avoid laxative use. No specific interaction with alcohol, but excess alcohol can affect electrolyte balance.
SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) from maternal use could indirectly affect the fetus. First trimester: No known teratogenic effects. Second/Third trimester: Risk of maternal electrolyte imbalance may impact fetal development. Use only if clearly needed.
No adequate studies in pregnant women. Animal reproduction studies not conducted. Sodium polystyrene sulfonate is not absorbed systemically, so fetal exposure is minimal. However, potential maternal electrolyte disturbances (e.g., hypokalemia) may indirectly affect the fetus. Risk cannot be ruled out; use only if clearly needed.
Excretion into breast milk is unlikely due to non-absorbable nature. M/P ratio not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal use is prolonged.
Not absorbed systemically; excretion into breast milk is unlikely. However, consider potential effects on infant electrolyte balance if maternal electrolyte disturbances occur. No M/P ratio available; use with caution in breastfeeding women.
No pharmacokinetic changes expected due to lack of absorption. Standard dosing may be used, but monitor electrolytes frequently due to altered renal function and volume of distribution in pregnancy. Dose adjustments are not required, but lower doses may suffice to avoid severe electrolyte shifts.
No specific dose adjustments required due to pregnancy-related pharmacokinetic changes, as drug is not absorbed. Administer same dose as for nonpregnant adults, but monitor electrolytes closely.
SPS (sodium polystyrene sulfonate) is a potassium-lowering resin that exchanges sodium for potassium in the GI tract. Administer orally or as a retention enema. Monitor for hypokalemia, hypomagnesemia, and sodium overload. Contraindicated in patients with bowel obstruction, severe constipation, or postoperative ileus due to risk of intestinal necrosis. Use with caution in patients on NSAIDs or with risk of colonic necrosis. Do not mix with sorbitol; use of sorbitol increases risk of intestinal necrosis. Monitor serum potassium levels frequently.
Sodium polystyrene sulfonate (SPS) exchanges sodium for potassium in the colon. Onset of action is 2-12 hours (oral) or 30-60 minutes (rectal). Monitor for hypokalemia, hypomagnesemia, and sodium overload, especially in patients with renal impairment, heart failure, or hypertension. Do not administer orally in patients with impaired bowel motility (e.g., postoperative ileus, constipation) due to risk of colonic necrosis. Concurrent use with sorbitol increases risk of intestinal necrosis; avoid sorbitol-containing formulations. SPS is less effective than newer potassium binders (patiromer, sodium zirconium cyclosilicate). Rectal administration is preferred when rapid effect needed, but ensure enema is retained for at least 30-60 minutes. Each gram of SPS exchanges approximately 1 m Eq of potassium but also delivers 1 m Eq of sodium, which can worsen fluid overload.
Take this medication exactly as prescribed, usually 1 to 4 times a day.,Do not mix SPS with orange juice or other fruit juices; it should be mixed with water or syrup.,This medication may cause constipation, so drink plenty of fluids and eat high-fiber foods.,If you experience severe constipation, severe abdominal pain, vomiting, or blood in vomit or stool, seek medical attention immediately.,Avoid taking other medications within 3 hours of SPS as it may bind to them and reduce their effectiveness.,Inform your doctor if you have a history of bowel obstruction, constipation, or kidney disease.,Do not use sorbitol or other laxatives with SPS unless directed by your doctor.
Take this medication exactly as prescribed, usually 1 to 4 times daily.,For oral suspension, mix the powder with water or another liquid (not juice) as directed and drink immediately. Do not mix with orange juice or other potassium-containing liquids.,Do not take this medication within 3 hours of any other oral medication to prevent absorption issues.,This medication may cause constipation or stomach upset. Tell your doctor if you have severe constipation, rectal bleeding, or severe stomach pain.,Avoid using laxatives or stool softeners unless directed by your doctor due to increased risk of bowel problems.,This drug exchanges sodium for potassium, so it may increase your sodium levels. Monitor salt intake if you have high blood pressure or heart failure.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, or signs of low potassium (e.g., confusion, leg cramps).,Keep this medication out of reach of children and do not use if the powder has changed color or consistency.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPS vs SODIUM POLYSTYRENE SULFONATE, answered by our medical review team.
SPS is a Potassium Binder that works by SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.. SODIUM POLYSTYRENE SULFONATE is a Potassium Binder that works by Sodium polystyrene sulfonate is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the large intestine, thereby reducing serum potassium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPS and SODIUM POLYSTYRENE SULFONATE depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPS is: 15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.. The standard adult dose of SODIUM POLYSTYRENE SULFONATE is: Adults: 15 g orally once daily to four times daily, as a single dose or suspension in water or syrup (3-4 m L per gram of resin). May also be administered rectally as a retention enema: 30-50 g every 6-8 hours, retained for at least 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPS and SODIUM POLYSTYRENE SULFONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPS is classified as Category C. SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) fr. SODIUM POLYSTYRENE SULFONATE is classified as Category C. No adequate studies in pregnant women. Animal reproduction studies not conducted. Sodium polystyrene sulfonate is not absorbed systemically, so fetal exposure is minimal. However, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.